Minerva Neurosciences, Inc. (NERV) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 4.47 |
| Open | 4.5 |
| Day High | 4.74 |
| Day Low | 4.38 |
| 52-Week High | 12.46 |
| 52-Week Low | 1.57 |
| Volume | 161,751 |
| Average Volume | 184,412 |
| Market Cap | 32.59M |
| PE | -0.13 |
| EPS | -37.03 |
| Moving Average 50 Days | 5.53 |
| Moving Average 200 Days | 4.67 |
| Change | 0.19 |
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
GlobeNewswire Inc.
Mar 04, 2026 12:00 PM GMT
BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Rem
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
GlobeNewswire Inc.
Jan 26, 2026 12:00 PM GMT
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it w
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
GlobeNewswire Inc.
Nov 19, 2025 1:30 PM GMT
BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appoi